Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer

Cancer Control

Volumn 23, Issue 4, 2016, Pages 327-337

  Hamel, Lauren M ^a   Penner, Louis A ^a   Albrecht, Terrance L ^a   Heath, Elisabeth ^a   Gwede, Clement K ^a,b   Eggly, Susan ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); DOCTOR PATIENT RELATION; ETHNIC GROUP; EVIDENCE BASED MEDICINE; FAMILY ATTITUDE; HEALTH CARE DISPARITY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH PERSONNEL ATTITUDE; HUMAN; INTERPERSONAL COMMUNICATION; MALIGNANT NEOPLASTIC DISEASE; PATIENT ATTITUDE; PATIENT PARTICIPATION; RACE DIFFERENCE; ETHNOLOGY; FEMALE; MINORITY GROUP; NEOPLASM; PATIENT SELECTION; PROCEDURES;

CLINICAL TRIALS AS TOPIC; ETHNIC GROUPS; FEMALE; HUMANS; MINORITY GROUPS; NEOPLASMS; PATIENT SELECTION;

EID: 84994493983     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481602300404     Document Type: Article

References (130)

1. Newman LA, Roff NK, Weinberg AD. Cancer clinical trials accrual:missed opportunities to address disparities and missed opportunities to improve outcomes for all. Ann Surg Oncol. 2008; 15(7): 1818-1819.
2. Nass SJ, Moses HL, Mendelsohn, eds; Committee on Cancer Clinical Trials; NCI Cooperative Group Program; Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Washington, DC: National Academies Press; 2010.
3. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291(22): 2720-2726.
4. Stewart JH, Bertoni AG, Staten JL, et al. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol. 2007; 14(12): 3328-3334.
5. Cheng SK, Dietrich MS, Dilts DM. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin Cancer Res. 2010; 16(22): 5557-5563.
6. Korn EL, Freidlin B, Mooney M, et al. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007. J Clin Oncol. 2010; 28(35): 5197-5201.
7. Penner LA, Manning M, Eggly S, et al. Prosocial behavior in cancer research: patient participation in cancer clinical trials. In: Graziano B, Schroeder D, eds. Handbook of Prosocial Behavior. Oxford, UK: Oxford University Press; 2014.
8. Minasian LM, Carpenter WR, Weiner BJ, et al. Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program. Cancer. 2010; 116(19): 4440-4449.
9. Du W, Gadgeel SM, Simon MS. Predictors of enrollment in lung cancer clinical trials. Cancer. 2006; 106(2): 420-425.
10. Al-Refaie WB, Vickers SM, Zhong W, et al. Cancer trials versus the real world in the United States. Ann Surg. 2011; 254(3): 438-442.
11. Freedman LS, Simon R, Foulkes MA, et al. Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993-the perspective of NIH clinical trialists. Control Clin Trials. 1995; 16(5): 277-285.
12. Kwiatkowski K, Coe K, Bailar JC, et al. Inclusion of minorities and women in cancer clinical trials, a decade later: have we improved? Cancer. 2013; 119(16): 2956-8.
13. Unger JM, Hershman DL, Albain KS, et al. Patient income level and cancer clinical trial participation. J Clin Oncol. 2013; 31(5): 536-542.
14. Baquet CR, Commiskey P, Daniel Mullins C, et al. Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors. Cancer Detect Prev. 2006; 30(1): 24-33.
15. Paskett ED, Cooper MR, Stark N, et al. Clinical trial enrollment of rural patients with cancer. Cancer Pract. 2002; 10(1): 28-35.
16. Vanderpool RC, Kornfeld J, Mills L, et al. Rural-urban differences in discussions of cancer treatment clinical trials. Patient Educ Couns. 2011; 85(2): e69-e8.
17. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socio-economic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4): 212-236.
18. American Cancer Society. Cancer Facts & Figures 2016. Atlanta, GA:American Cancer Society. http://www.cancer.org/acs/groups/content/@ research/documents/document/acspc-047079.pdf. Accessed September 13, 2016.
19. American Cancer Society. Cancer Facts & Figures for African Americans 2016-2018. Atlanta, GA: American Cancer Society. http://www.cancer.org/acs/ groups/content/@editorial/documents/document/acspc-047403.pdf. Accessed September 13, 2016.
20. Banda DR, St. Germain D, McCaskill-Stevens W, et al. A critical review of the enrollment of black patients in cancer clinical trials. ASCO Org. 2012:153-157.
21. Carpenter WR, Tyree S, Wu Y, et al. A surveillance system for monitoring, public reporting, and improving minority access to cancer clinical trials. Clin Trials. 2012; 9(4): 426-435.
22. Unger JM, Gralow JR, Albain KS, et al. Patient income level and cancer clinical trial participation: a prospective survey study. JAMA Oncol. 2016; 2(1): 137-139.
23. Smedley BD, Stith AY, Nelson AR, eds; Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care; Board on Health Sciences Policy; Institute of Medicine. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academies Press; 2003.
24. Bolen S, Tilburt J, Baffi C, et al. Defining "success" in recruitment of underrepresented populations to cancer clinical trials: moving toward a more consistent approach. Cancer. 2006; 106(6): 1197-1204.
25. Taplin SH, Anhang Price R, Edwards HM, et al. Understanding and influencing multilevel factors across the cancer care continuum. J Natl Cancer Inst Monogr. 2012; 2012(44): 2-10.
26. Clauser SB, Taplin SH, Foster MK, et al. Multilevel intervention research:lessons learned and pathways forward. J Natl Cancer Inst Monogr. 2012; 2012(44): 127-133.
27. Kozlowski SWJ, Klein KJ. A multilevel approach to theory and research in organizations: contextual, temporal, and emergent processes. In: Klein KJ, Koszlowski SWJ, eds. Multilevel Theory, Research, and Methods in Organizations: Foundations, Extensions, and New Directions. San Francisco: Jossey-Bass; 2000.
28. Diehl KM, Green EM, Weinberg A, et al. Features associated with successful recruitment of diverse patients onto cancer clinical trials: report from the American College of Surgeons Oncology Group. Ann Surg Oncol. 2011; 18(13): 3544-3550.
29. Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008; 112(2): 228-242.
30. Langford AT, Resnicow K, Dimond EP, et al. Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute’s Community Cancer Centers Program. Cancer. 2014; 120(6): 877-884.
31. Bruner DW, Jones M, Buchanan D, et al. Reducing cancer disparities for minorities: a multidisciplinary research agenda to improve patient access to health systems, clinical trials, and effective cancer therapy. J Clin Oncol. 2006; 24(14): 2209-2215.
32. McCaskill-Stevens W, McKinney MM, Whitman CG, et al. Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experience. J Clin Oncol. 2005; 23(22): 5247-5254.
33. Somkin CP, Altschuler A, Ackerson L, et al. Organizational barriers to physician participation in cancer clinical trials. Am J Manag Care. 2005; 11(7): 413-421.
34. Wong YN, Schluchter MD, Albrecht TL, et al. Financial concerns about participation in clinical trials among patients with cancer. J Clin Oncol. 2016; 34(5): 479-487.
35. Sateren WB, Trimble EL, Abrams J, et al. How socio-demographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002; 20(8): 2109-2117.
36. Farmer DF, Jackson SA, Camacho F, et al. Attitudes of African American and low socio-economic status white women toward medical research. Health Care Poor Underserved. 2007; 18(1): 85-99.
37. Paskett ED, Reeves KW, McLaughlin JM, et al. Recruitment of minority and underserved populations in the United States: the Centers for Population Health and Health Disparities experience. Contemp Clin Trials. 2008; 29(6): 847-861.
38. Skloot R. The Immortal Life of Henrietta Lacks. New York: Broadway Books; 2011.
39. Katz RV, Kegeles SS, Kressin NR, et al. Awareness of the Tuskegee syphilis study and the US presidential apology and their influence on minority participation in biomedical research. Am J Public Health. 2008; 98(6): 1137-1142.
40. Shavers VL, Lynch CF, Burmeister LF. Racial differences in factors that influence the willingness to participate in medical research studies. Ann Epidemiol. 2002; 12(4): 248-256.
41. Weiner BJ, Jacobs SR, Minasian LM, et al. Organizational designs for achieving high treatment trial enrollment: a fuzzy set analysis of the Community Clinical Oncology Program. J Oncol Pract. 2012; 8(5): 287-291.
42. Wujcik D, Wolff SN. Recruitment of African Americans to national oncology clinical trials through a clinical trial shared resource. J Health Care Poor Underserved. 2010; 21(1 suppl): 38-50.
43. McCaskill-Stevens W, Lyss AP, Good M, et al. The NCI Community Oncology Research Program: what every clinician needs to know. Am Soc Clin Oncol Educ Book. 2013.
44. Brooks SE, Muller CY, Robinson W, et al. Increasing minority enrollment onto clinical trials: practical strategies and challenges emerge from the NRG Oncology Accrual Workshop. J Oncol Pract. 2015; 11(6): 486-490.
45. Brown R, Albrecht TL. Enrollment in clinical trials. In: Kissane D, Bultz BD, Butow PN, et al, eds. Handbook of Communication in Oncology and Palliative Care. Oxford, UK: Oxford University Press; 2010.
46. Howerton MW, Gibbons MC, Baffi CR, et al. Provider roles in the recruitment of underrepresented populations to cancer clinical trials. Cancer. 2007; 109(3): 465-476.
47. Henderson GE, Churchill LR, Davis AM, et al. Clinical trials and medical care: defining the therapeutic misconception. PLoS Med. 2007;4(11):e324.
48. Pinto HA, McCaskill-Stevens W, Wolfe P, et al. Physician perspectives on increasing minorities in cancer clinical trials: an Eastern Cooperative Oncology Group (ECOG) initiative. Ann Epidemiol. 2000; 10(8 suppl): S78-S84.
49. Hagiwara N, Penner LA, Gonzalez R, et al. Racial attitudes, physician- patient talk time ratio, and adherence in racially discordant medical interactions. Soc Sci Med. 2013; 87: 123-131.
50. Cooper LA, Roter DL, Carson KA, et al. The associations of clinicians’ implicit attitudes about race with medical visit communication and patient ratings of interpersonal care. Am J Public Health. 2012; 102(5): 979-987.
51. Blair IV, Steiner JF, Fairclough DL, et al. Clinicians’ implicit ethnic/ racial bias and perceptions of care among black and Latino patients. Ann Fam Med. 2013; 11(1): 43-52.
52. Penner LA, Dovidio JF, West TV, et al. Aversive racism and medical interactions with Black patients: a field study. J Exp Soc Psychol. 2010; 46(2): 436-440.
53. van Ryn M, Burgess D, Malat J, et al. Physicians’ perceptions of patients’ social and behavioral characteristics and race disparities in treatment recommendations for men with coronary artery disease. Am J Public Health. 2006; 96(2): 351-357.
54. Moskowitz D, Thom DH, Guzman D, et al. Is primary care providers’ trust in socially marginalized patients affected by race? J Gen Intern Med. 2011;26(8):846-851.
55. Moskowitz GB, Stone J, Childs A. Implicit stereotyping and medical decisions: unconscious stereotype activation in practitioners’ thoughts about African Americans. Am J Public Health. 2012; 102(5): 996-1001.
56. Sabin JA, Greenwald AG. The influence of implicit bias on treatment recommendations for 4 common pediatric conditions: pain, urinary tract infection, attention deficit hyperactivity disorder, and asthma. Am J Public Health. 2012; 102(5): 988-995.
57. Sabin JA, Rivara FP, Greenwald AG. Physician implicit attitudes and stereotypes about race and quality of medical care. Med Care. 2008; 46(7): 678-685.
58. Joseph G, Dohan D. Diversity of participants in clinical trials in an academic medical center: the role of the ‘Good Study Patient?'. Cancer. 2009; 115(3): 608-615.
59. Simon MS, Du W, Flaherty L, et al. Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol. 2004; 22(11): 2046-2052.
60. Penner LA, Blair IV, Albrecht TL, et al. Reducing racial health care disparities: a social psychological analysis. Policy Insights Behav Brain Sci. 2014; 1: 204-212.
61. Epstein RM, Street RL Jr. Patient-Centered Communication in Cancer Care: Promoting Healing and Reducing Suffering. NIH publication no. 07-6225. Bethesda, MD: National Cancer Institute; 2007.
62. Kissane DW, Bylund CL, Banerjee SC, et al. Communication skills training for oncology professionals. J Clin Oncol. 2012; 30(11): 1242-1247.
63. Brown RF, Butow PN, Boyle F, et al. Seeking informed consent to cancer clinical trials: evaluating the efficacy of doctor communication skills training. Psychooncology. 2007; 16(6): 507-516.
64. Gross CP, Herrin J, Wong N, et al. Enrolling older persons in cancer trials: the effect of socio-demographic, protocol, and recruitment center characteristics. J Clin Oncol. 2005; 23(21): 4755-4763.
65. Manne S, Kashy D, Albrecht T, et al. Attitudinal barriers to participation in oncology clinical trials: factor analysis and correlates of barriers. Eur J Cancer Care (Engl). 2015; 24(1): 28-38.
66. Rivers D, August EM, Sehovic I, et al. A systematic review of the factors influencing African Americans’ participation in cancer clinical trials. Contemp Clin Trials. 2013; 35(2): 13-32.
67. Wendler D, Kington R, Madans J, et al. Are racial and ethnic minorities less willing to participate in health research? PLoS Med. 2006;3(2):e19.
68. Svensson K, Ramirez OF, Peres F, et al. Socio-economic determinants associated with willingness to participate in medical research among a diverse population. Contemp Clin Trials. 2012; 33(6): 1197-1205.
69. Katz RV, Kegeles SS, Kressin NR, et al. The Tuskegee Legacy Project:willingness of minorities to participate in biomedical research. J Health Care Poor Underserved. 2006; 17(4): 698-715.
70. Meropol NJ, Wong YN, Albrecht T, et al. Randomized trial of a web-based intervention to address barriers to clinical trials. J Clin Oncol. 2016; 34(5): 469-478.
71. Jacobsen PB, Wells KJ, Meade CD, et al. Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicenter randomized controlled trial. J Clin Oncol. 2012; 30(20): 2516-2521.
72. Corbie-Smith G, Thomas SB, Williams MV, et al. Attitudes and beliefs of African Americans toward participation in medical research. J Gen Intern Med. 1999; 14(9): 537-546.
73. Scharff DP, Mathews KJ, Jackson P, et al. More than Tuskegee:understanding mistrust about research participation. J Health Care Poor Underserved. 2010; 21(3): 879-897.
74. Dovidio JF, Penner LA, Albrecht TL, et al. Disparities and distrust:the implications of psychological processes for understanding racial disparities in health and health care. Soc Sci Med. 2008; 67(3): 478-486.
75. Penner LA, Dovidio JF, Edmondson D, et al. The experience of discrimination and black-white health disparities in medical care. J Black Psychol. 2009; 35(2): 180-203.
76. Halbert CH, Armstrong K, Gandy OH Jr, et al. Racial differences in trust in health care providers. Arch Intern Med. 2006; 166(8): 896-901.
77. Halbert CH, Weathers B, Delmoor E, et al. Racial differences in medical mistrust among men diagnosed with prostate cancer. Cancer. 2009; 115(11): 2553-2561.
78. Boulware L, Cooper L, Ratner L, et al. Race and trust in the health care system. Public Health Reports. 2003; 118: 358-365.
79. Duda C, Mahon I, Chen MH, et al. Impact and costs of targeted recruitment of minorities to the National Lung Screening Trial. Clin Trials. 2011; 8(2): 214-223.
80. Jean-Pierre P, Fiscella K, Griggs J, et al. Race/ethnicity-based concerns over understanding cancer diagnosis and treatment plan. J Natl Med Assoc. 2010; 102(3): 184-189.
81. Street RL Jr, Gordon H, Haidet P. Physicians’ communication and perceptions of patients: is it how they look, how they talk, or is it just the doctor? Soc Sci Med. 2007; 65(3): 586-8.
82. Eggly S, Harper FW, Penner LA, et al. Variation in question asking during cancer clinical interactions: a potential source of disparities in access to information. Patient Educ Couns. 2011; 82(1): 63-68.
83. Cooper LA, Roter DL, Johnson RL, et al. Patient-centered communication, ratings of care, and concordance of patient and physician race. Ann Intern Med. 2003; 139(11): 907-915.
84. Johnson RL, Roter D, Powe NR, et al. Patient race/ethnicity and quality of patient-physician communication during medical visits. Am J Public Health. 2004; 94(12): 2084-2090.
85. Gordon HS, Street RL Jr, Sharf BF, et al. Racial differences in trust and lung cancer patients’ perceptions of physician communication. J Clin Oncol. 2006; 24(6): 904-909.
86. Gordon HS, Street RL Jr, Sharf BF, et al. Racial differences in doctors’ information-giving and patients’ participation. Cancer. 2006; 107(6): 1313-1320.
87. Siminoff LA, Graham GC, Gordon NH. Cancer communication patterns and the influence of patient characteristics: disparities in informationgiving and affective behaviors. Patient Educ Couns. 2006; 62(3): 355-360.
88. Song L, Hamilton JB, Moore AD. Patient-healthcare provider communication:perspectives of African American cancer patients. Health Psychol. 2012; 31(5): 539-547.
89. Sabin J, Nosek BA, Greenwald A, et al. Physicians’ implicit and explicit attitudes about race by MD race, ethnicity, and gender. J Health Care Poor Underserved. 2009; 20(3): 896-913.
90. Penner LA, Dovidio JF, Gonzalez R, et al. The effects of oncologist implicit racial bias in racially discordant oncology interactions. J Clin Oncol. 2016; 34(24): 2874-2880.
91. Janz NK, Wren PA, Copeland LA, et al. Patient-physician concordance:preferences, perceptions, and factors influencing the breast cancer surgical decision. J Clin Oncol. 2004; 22(15): 3091-3098.
92. Albrecht TL, Eggly SS, Gleason ME, et al. Influence of clinical communication on patients’ decision making on participation in clinical trials. J Clin Oncol. 2008; 26(16): 2666-2673.
93. Eggly S, Albrecht TL, Harper FW, et al. Oncologists’ recommendations of clinical trial participation to patients. Patient Educ Couns. 2008; 70(1): 143-148.
94. Barton E, Eggly S. Ethical or unethical persuasion? The rhetoric of offers to participate in clinical trials. Writ Commun. 2009; 26(3): 295-319.
95. Kass N, Taylor H, Fogarty L, et al. Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear? J Empir Res Hum Res Ethics. 2008; 3(3): 57-8.
96. Eggly S, Barton E, Winckles A, et al. A disparity of words: racial differences in oncologist-patient communication about clinical trials. Health Expect. 2015; 18(5): 1316-1326.
97. Hamel LM, Chapman R, Malloy M, et al. Critical shortage of African American medical oncologists in the United States. J Clin Oncol. 2015; 33(32): 3697-3700.
98. Street RL Jr, Slee C, Kalauokalani DK, et al. Improving physicianpatient communication about cancer pain with a tailored education-coaching intervention. Patient Educ Couns. 2010; 80(1): 42-47.
99. Kass NE, Sugarman J, Medley AM, et al. An intervention to improve cancer patients’ understanding of early-phase clinical trials. IRB. 2009; 31(3): 1-10.
100. Brown RF, Bylund CL, Li Y, et al. Testing the utility of a cancer clinical trial specific question prompt list (QPL-CT) during oncology consultations. Patient Educ Couns. 2012; 88(2): 311-317.
101. Gaertner S, Dovidio JF. A common ingroup identity: a categorization- based approach for reducing intergroup bias. In: Nelson TD, ed. Handbook of Prejudice, Stereotyping, and Discrimination. Thousand Oaks, CA: Sage; 2009.
102. Gaertner S, Dovidio JF, Houlette M. Social categorization. In: Dovidio JF, Hewstone M, Glick P, eds. Handbook of Prejudice, Stereotyping, and Discrimination. London: Sage; 2010.
103. Penner LA, Gaertner S, Dovidio JF, et al. A social psychological approach to improving the outcomes of racially discordant medical interactions. J Gen Intern Med. 2013; 28(9): 1143-1149.
104. Stange KC, Breslau ES, Dietrich AJ, et al. State-of-the-art and future directions in multilevel interventions across the cancer control continuum. J Natl Cancer Inst Monogr. 2012; 2012(44): 20-31.
105. Albrecht TL, Penner LA, Cline RJ, et al. Studying the process of clinical communication: issues of context, concepts, and research directions. J Health Commun. 2009; 14(suppl 1): 47-56.
106. McCormack LA, Treiman K, Rupert D, et al. Measuring patient-centered communication in cancer care: a literature review and the development of a systematic approach. Soc Sci Med. 2011; 72(7): 1085-1095.
107. Epstein RM, Street RL Jr. Patient-Centered Communication in Cancer Care: Promoting Healing and Reducing Suffering. NIH publication no. 07-6225. Bethesda, MD: National Cancer Institute; US Department of Health and Human Services, National Institutes of Health; 2007.
108. Sansoni JE, Grootemaat P, Duncan C. Question Prompt Lists in health consultations: a review. Patient Educ Couns. 2015. Epub ahead of print.
109. Brandes K, Linn AJ, Butow PN, et al. The characteristics and effectiveness of question prompt list interventions in oncology: a systematic review of the literature. Psychooncology. 2015; 24(3): 245-252.
110. Dimoska A, Tattersall MH, Butow PN, et al. Can a "prompt list" empower cancer patients to ask relevant questions? Cancer. 2008; 113(2): 225-8.
111. Henselmans I, de Haes HC, Smets EM. Enhancing patient participation in oncology consultations: a best evidence synthesis of patient-targeted interventions. Psychooncology. 2013; 22(5): 961-977.
112. Dimoska A, Butow PN, Dent E, et al. An examination of the initial cancer consultation of medical and radiation oncologists using the Cancode interaction analysis system. Br J Cancer. 2008; 98(9): 1508-1514.
113. Cegala DJ, Street RL Jr, Clinch CR. The impact of patient participation on physicians’ information provision during a primary care medical interview. Health Commun. 2007; 21(2): 177-185.
114. Street RL, Jr, Tancredi DJ, Slee C, et al. A pathway linking patient participation in cancer consultations to pain control. Psychooncology. 2014; 23(10): 1111-1117.
115. Clayton JM, Butow PN, Tattersall MH, et al. Randomized controlled trial of a prompt list to help advanced cancer patients and their caregivers to ask questions about prognosis and end-of-life care. J Clin Oncol. 2007; 25(6): 715-723.
116. Greene J, Hibbard JH. Why does patient activation matter? An examination of the relationships between patient activation and healthrelated outcomes. J Gen Intern Med. 2012; 27(5): 520-526.
117. Clayton J, Butow P, Tattersall M, et al. Asking questions can help:development and preliminary evaluation of a question prompt list for palliative care patients. Br J Cancer. 2003; 89(11): 2069-2077.
118. Cegala DJ, Chisolm DJ, Nwomeh BC. A communication skills intervention for parents of pediatric surgery patients. Patient Educ Couns. 2013; 93(1): 34-39.
119. Eggly S, Tkatch R, Penner LA, et al. Development of a question prompt list as a communication intervention to reduce racial disparities in cancer treatment. J Cancer Educ. 2013; 28(2): 282-289.
120. Eggly S, Hamel LM, Foster T, et al. Using a question prompt list to increase patient active participation in racially discordant cancer interactions. Presented at: 13th International Conference on Communication in Healthcare; October 25-28, 2015; New Orleans, LA.
121. Brown RF, Cadet DL, Houlihan RH, et al. Perceptions of participation in a phase I, II, or III clinical trial among African American patients with cancer: what do refusers say? J Oncol Pract. 2013; 9(6): 287-8.
122. Bylund CL, Brown R, Gueguen JA, et al. The implementation and assessment of a comprehensive communication skills training curriculum for oncologists. Psychooncology. 2010; 19(6): 583-593.
123. Wendler D, Grady C. What should research participants understand to understand they are participants in research? Bioethics. 2008; 22(4): 203-8.
124. Council for International Organizations of Medical Sciences (CIOMS); World Health Organization. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva: CIOMS; 2002.
125. Back AL, Arnold RM, Baile WF, et al. Approaching difficult communication tasks in oncology. CA Cancer J Clin. 2005; 55(3): 164-177.
126. Kemp EC, Floyd MR, McCord-Duncan E, et al. Patients prefer the method of "tell back-collaborative inquiry" to assess understanding of medical information. J Am Board Fam Med. 2008; 21(1): 24-30.
127. Makoul G, Clayman ML. An integrative model of shared decision making in medical encounters. Patient Educ Couns. 2006; 60(3): 301-312.
128. Young AI, Fazio RH. Attitude accessibility as a determinant of object construal and evaluation. J Exp Soc Psychol. 2013; 49(3): 404-418.
129. Gollwitzer P. The volitional benefits of planning. In: Gollwitzer P, Bargh J, eds. The Psychology of Action: Linking Cognition and Motivation to Behaviour. New York: Guilford Press; 1996.
130. Gollwitzer PM. Implementation intentions: strong effects of simple plans. Am Psychologist. 1999; 54(7): 493-503.